•  
  •  
 

Abstract

Objectives: To investigate and establish the relationship between the use of statin therapy and the risk of development of diabetes. Methods: PubMed and the Cochrane Central Register of Controlled Trials was searched for randomized controlled end-point trials of statins, with more than 1000 subjects and a minimum of one-year follow-up period, published until August 2015. The odds ratio (OR) of diabetes incidence with overall statin therapy as well as with different statins in question was calculated through random effect meta-analysis model. Results: Fourteen studies were included in the analysis with a total of 94,943 participants. Of these, 2392 subjects developed incident diabetes in the statin and 2167 in the placebo groups during a 4-year follow-up. The OR of diabetes incidence with statin therapy was significantly higher as compared with the placebo group (OR=1.11; 95% confidence interval = 1.0 to 1.2; p =0.007). There was an insignificant level of heterogeneity between the included trials (Cochran Q= 19.463, p =0.109, I 2 =33.20). Subgroup analysis showed that only 2 statins namely, atorvastatin (OR= 1.29; p =0.042) and rosuvastatin (OR = 1.17; p x=0.01) were significantly associated. Conclusion: Statin therapy can slightly increase risk of incident diabetes in subjects with hypercholesterolemia.

Article Type

Review

First Page

1051

Last Page

1060

Download

Share

COinS